The aromatase inhibitors in early breast cancer: who, when and why?

Glen Pater
Med J Aust 2006; 184 (1): . || doi: 10.5694/j.1326-5377.2006.tb00106.x
Published online: 2 January 2006

Glen Pater

  • Glen Pater

  • Medical and Regulatory Affairs, AstraZeneca Australia, PO Box 131, North Ryde, NSW 1670.

Correspondence: Glen.Pater@ASTRAZENECA.COM


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.